|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/46 | (2006.01) |
| A61P 1/16 | (2006.01) | ||
| A61P 3/00 | (2006.01) |
| (11) | Number of the document | 3518962 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17791485.0 |
| Date of filing the European patent application | 2017-09-28 | |
| (97) | Date of publication of the European application | 2019-08-07 |
| (45) | Date of publication and mention of the grant of the patent | 2021-06-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/053961 |
| Date | 2017-09-28 |
| (87) | Number | WO 2018/064303 |
| Date | 2018-04-05 |
| (30) | Number | Date | Country code |
| 201662402183 P | 2016-09-30 | US | |
| 201662420233 P | 2016-11-10 | US | |
| 201762456511 P | 2017-02-08 | US |
| (72) |
QUINN, Anthony , US
GOODMAN, Zachary , US
BURTON, Barbara , US
RANKIN, Andrew , US
FRIEDMAN, Mark , US
SONI, Paresh , US
|
| (73) |
Alexion Pharmaceuticals, Inc. ,
121 Seaport Boulevard, Boston, MA 02210,
US
|
| (54) | SEBELIPASE ALFA FOR USE IN LIVER FIBROSIS AND TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS BASED ON ISHAK FIBROSIS STAGE |
| SEBELIPASE ALFA FOR USE IN LIVER FIBROSIS AND TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS BASED ON ISHAK FIBROSIS STAGE |